Provides pharmaceutical contract development and manufacturing services, supporting drug development, testing, and production processes.
2005
China
1,001 - 5,000 employees
Pharmaceuticals
$100M - 500M in revenue
$10M - 25M in profitability
Total Annual
Revenue & EBITDA
($ B)
Margin as % of revenue
R&D as % of revenue
Analyst consensus vs actuals
($ B)
0.5
▼ 9.0%
0.4
▼ 0.0%
0.5
▼ 3.3%
6.4
2031Available
Available
Not available
Available
3 out of 14 incl. management
| Target | Status | Temperature alignment | Year |
|---|---|---|---|
| Near-term target | Targets set | 1.5°C | 2030 |
| Long-term target | Not disclosed | - | - |
| Net-zero | Not disclosed | - | - |
| Business Ambition 1.5°C | Not disclosed | - | - |
Porton Pharma Solutions Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2023 base year. Porton Pharma Solutions Ltd. also commits to reduce absolute scope 3 GHG emissions covering purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, and processing of sold products 25% within the same timeframe.
Powered by illuminem and Science Based Targets initiative. Last updated: 20 Mar 2025Not available
Not available
Not available
Not available
Not available
Not available
Not available
Climate Score
B
Water Score
B-
A
A-
B
B-
C
C-
D
D-